Oral Cancer

Oral cancer encompasses malignancies of the lips, tongue, floor of the mouth, cheeks, hard palate, and oropharynx — a group of cancers collectively accounting for approximately 54,000 new diagnoses and 11,000 deaths in the United States each year. Until the 1990s, oral cancer was almost exclusively a disease of older adults who smoked and drank heavily. That epidemiology has shifted dramatically with the emergence of human papillomavirus (HPV), particularly HPV-16, as the dominant cause of oropharyngeal cancers — the cancer rising fastest in young, non-smoking adults. HPV-positive oropharyngeal cancer and HPV-negative oral cavity cancer are now recognized as biologically distinct diseases with different risk factors, treatment responses, and prognoses, shaping one of the most significant paradigm shifts in head and neck oncology over the past two decades.

Table of Contents

1. Overview and Epidemiology
2. Risk Factors — Two Distinct Diseases
3. Premalignant Lesions and Field Cancerization
4. Clinical Presentation and Warning Signs
5. Diagnosis
6. Staging
7. Treatment — Surgery
8. Treatment — Radiation and Chemoradiation
9. Systemic Therapy for Recurrent and Metastatic Disease
10. Reconstruction and Quality of Life
11. Prevention and Early Detection
12. Key Research Papers
13. PubMed Topic Searches
14. Connections
15. Featured Videos

Overview and Epidemiology

Oral cancer is not a single entity but a spectrum of malignancies arising from the squamous epithelium lining the oral cavity and oropharynx. Squamous cell carcinoma (SCC) accounts for more than 90% of all oral cancers, with the remainder comprising mucoepidermoid carcinoma, adenoid cystic carcinoma, and other rare salivary gland tumors.

The American Cancer Society estimates approximately 54,540 new cases of oral cavity and oropharyngeal cancer in the United States in 2024, resulting in roughly 11,580 deaths. Globally, the burden is far heavier: Ferlay and colleagues documented over 400,000 new oral cancer cases worldwide annually, with the highest incidence rates in South and Southeast Asia, driven by widespread betel nut chewing.

Two anatomic subgroups carry distinct epidemiological profiles:

• Oral cavity cancer — lips, anterior two-thirds of the tongue, floor of mouth, buccal mucosa, hard palate, upper and lower alveolar ridge, and retromolar trigone. Strongly linked to tobacco and alcohol. Most common sites: tongue (38% of oral cavity tumors), floor of mouth, lower lip.
• Oropharyngeal cancer (OPC) — base of tongue, soft palate, tonsils (palatine and lingual), and posterior pharyngeal wall. Increasingly dominated by HPV-16. The tonsil and base of tongue together account for roughly 85% of OPC cases.

The incidence of HPV-positive oropharyngeal cancer has risen sharply since the 1980s — by some estimates tripling or quadrupling in the United States. It now disproportionately affects white men aged 40–60, a demographic with historically low cancer risk. HPV-negative oral cavity cancer, by contrast, has declined modestly, likely reflecting decreasing tobacco use in Western nations.

Back to Table of Contents

Risk Factors — Two Distinct Diseases

HPV-Negative Oral Cavity Cancer

Tobacco is the single greatest risk factor for oral cavity cancer. Both smoked tobacco (cigarettes, cigars, pipes) and smokeless tobacco (snuff, chewing tobacco) dramatically elevate risk, with risk scaling directly with pack-years and duration of use. Smokeless tobacco is particularly associated with cancers of the buccal mucosa and gingiva, sites that are in prolonged direct contact with the product.

Alcohol acts as an independent carcinogen through its conversion to acetaldehyde, a direct DNA mutagen. Individuals with polymorphisms in CYP2E1 or ALDH2 metabolize ethanol more slowly, accumulating more acetaldehyde and carrying higher oral cancer risk. Consuming more than 14 alcoholic drinks per week significantly elevates risk. The effect is dose-dependent.

Combined tobacco and alcohol exposure produces a multiplicative — not merely additive — risk increase. Tobacco alone elevates risk 6-fold; alcohol alone roughly 3-fold; together the combined risk can reach 100-fold above baseline. The overwhelming majority of HPV-negative oral cavity cancer cases in Western countries involve this combination.

Betel nut (areca catechu) is the world's fourth most widely used psychoactive substance after tobacco, caffeine, and alcohol. Chewed with or without tobacco in a betel leaf quid (paan), it causes oral submucous fibrosis — a progressive fibrotic condition of the oral mucosa that is strongly premalignant — as well as direct carcinogenesis. Betel nut use is endemic in India, Pakistan, Bangladesh, Sri Lanka, Taiwan, Papua New Guinea, and Pacific Island communities, explaining the global oral cancer epidemic concentrated in these regions.

Chronic UV exposure is the major risk factor for lip cancer, particularly the lower lip, which is analogous to sun-exposed skin. Farmers, fishermen, and outdoor workers are at disproportionate risk. Actinic cheilitis (chronic sun-damaged lower lip) is the direct precursor lesion.

HPV-Positive Oropharyngeal Cancer

HPV-16 is implicated in more than 90% of HPV-associated oropharyngeal cancers, with HPV-18, 31, and 33 accounting for most remaining cases. The virus establishes persistent infection in the tonsillar crypts and base of tongue, integrating into the host genome and inactivating p53 and Rb tumor suppressors via the E6 and E7 oncoproteins.

Sexual behavior is the primary transmission route. The number of lifetime oral sex partners is the most strongly correlated behavioral risk factor. Later age of first sexual activity is protective. Women appear to have some protection from higher background HPV vaccination rates and possibly immunological differences, though female HPV-OPC is increasing.

The landmark 2010 New England Journal of Medicine paper by Ang and colleagues definitively established HPV status as the most important prognostic factor in oropharyngeal cancer. HPV-positive OPC carries dramatically better outcomes — 5-year overall survival of approximately 80–90% compared with 40–50% for HPV-negative OPC — reflecting fundamentally different biology, including intact p53 function, better DNA repair, and robust immune infiltration.

Back to Table of Contents

Premalignant Lesions and Field Cancerization

Several oral mucosal conditions are recognized as premalignant, with variable rates of progression to invasive carcinoma:

• Leukoplakia — a white patch or plaque that cannot be scraped off and cannot be attributed to another diagnosable condition. Histological findings range from hyperkeratosis without dysplasia (low risk) to severe dysplasia or carcinoma in situ (high risk). Overall malignant transformation rates range from 5–25%, highest in lesions on the floor of mouth, lateral tongue, and soft palate.
• Erythroplakia — a velvety red patch not attributable to another condition. Despite its rarity, erythroplakia carries a malignant transformation risk exceeding 50% and must be biopsied promptly.
• Erythroleukoplakia — mixed red and white lesions carry intermediate risk but tend to have higher dysplasia rates than pure leukoplakia.
• Oral submucous fibrosis (OSMF) — caused by betel nut, characterized by progressive submucosal fibrosis leading to trismus (inability to open the mouth) and mucosal rigidity. Malignant transformation risk is approximately 7–13%.
• Oral lichen planus — particularly the erosive (atrophic) type carries a small but real increased risk of oral SCC, estimated at approximately 1–3% over 10 years.

Field cancerization is a foundational concept first described by Slaughter and colleagues in 1953. Because tobacco smoke and alcohol bathe the entire upper aerodigestive tract — oral cavity, oropharynx, hypopharynx, larynx, and esophagus — the entire mucosal surface acquires premalignant genetic changes simultaneously. This explains:

• Synchronous primaries: 2–3% of patients have a second independent primary cancer at diagnosis, detectable by panendoscopy.
• Metachronous primaries: HPV-negative patients face a 3–5% annual risk of developing a second primary cancer in the aerodigestive tract, necessitating lifelong annual surveillance.

HPV-positive OPC does not follow the field cancerization model in the same way; risk is site-specific, and second primary rates in truly HPV-positive patients (who are non-smokers) are considerably lower.

Back to Table of Contents

Clinical Presentation and Warning Signs

Oral cancer is notorious for late diagnosis. Many early lesions are painless, and patients often delay seeking care for months. The following warning signs warrant urgent evaluation — any of these persisting for more than two weeks in an adult should prompt a referral:

• A persistent oral ulcer that does not heal — the single most important warning sign. Any non-healing ulcer, particularly on the lateral tongue or floor of mouth, is oral cancer until proven otherwise.
• Red or white patch in the mouth, especially on the tongue, gum, or cheek lining.
• Lump or thickening in the cheek, tongue, or neck.
• Difficulty chewing, swallowing, or moving the tongue or jaw — indicates locally advanced disease with muscular invasion.
• Unexplained tooth loosening — suggests alveolar bone invasion, often from gingival or floor of mouth tumors.
• Hoarseness or change in voice — raises concern for oropharyngeal or laryngeal involvement.
• Unilateral ear pain (referred otalgia) — a critically underappreciated sign. The oropharynx and base of tongue share sensory innervation with the ear via Jacobson's nerve (CN IX) and Arnold's nerve (CN X). Unexplained unilateral otalgia in an adult with a normal ear exam mandates oropharyngeal evaluation.
• Neck mass — cervical lymphadenopathy is frequently the presenting symptom of HPV-positive OPC. A cystic neck mass in a middle-aged or older adult should be regarded as HPV-OPC until proven otherwise; aspiration cytology or fine-needle biopsy is the first step.
• Late signs: trismus (reduced mouth opening, from pterygoid muscle invasion), skin involvement, and base of skull invasion indicate very advanced disease and significantly worsen prognosis.

Because early lesions are often painless and subtle, regular oral examinations by dentists and primary care physicians play a crucial role in detection. Unfortunately, many patients first present with Stage III or IV disease.

Back to Table of Contents

Diagnosis

A thorough head and neck examination is the starting point. Clinicians should inspect the entire oral cavity under good lighting with tongue depressors, palpate the tongue and floor of mouth bimanually, and assess neck nodes for size, firmness, and fixation. Flexible nasopharyngoscopy or indirect laryngoscopy extends the exam to the oropharynx, hypopharynx, and larynx.

Biopsy is mandatory for definitive diagnosis. Incisional biopsy (taking a representative sample) is preferred for larger lesions; small lesions may be completely excised (excisional biopsy). Punch biopsy is suitable for accessible mucosal lesions. Fine-needle aspiration cytology of a neck mass can rapidly confirm malignancy.

HPV testing is essential for all oropharyngeal SCC:

• p16 immunohistochemistry (IHC) — serves as a surrogate biomarker for high-risk HPV infection. Strong, diffuse p16 staining (>70% of tumor cells, >1+ intensity) has high sensitivity and specificity for HPV-associated OPC and is the standard initial test.
• HPV in situ hybridization (ISH) or PCR — confirms HPV presence and genotype when p16 is equivocal or for non-oropharyngeal sites.

Imaging is critical for staging:

• CT neck and chest with contrast — baseline locoregional staging; evaluates lymph nodes, bone involvement, and presence of lung metastases or synchronous lung primary.
• MRI — superior for soft-tissue delineation; particularly valuable for tongue base invasion, perineural spread, deep space extension, and skull base involvement.
• PET-CT — recommended for clinically N+ disease or Stage III–IV to detect distant metastases and guide treatment decisions. The PET-NECK trial (Mehanna 2016, NEJM) demonstrated PET-CT surveillance after chemoradiation is non-inferior to planned neck dissection for N2-N3 OPC, sparing many patients unnecessary surgery.

Panendoscopy under general anesthesia — direct laryngoscopy, esophagoscopy, and bronchoscopy — may be performed in HPV-negative patients to exclude synchronous primaries in the aerodigestive tract.

Back to Table of Contents

Staging

The AJCC 8th Edition (2017) introduced one of the most significant revisions in head and neck oncology staging history: separate staging systems for HPV-positive and HPV-negative oropharyngeal cancer, reflecting their distinct biological behavior and prognosis.

Oral Cavity Cancer (and HPV-Negative OPC)

• T1 — tumor ≤2 cm in greatest dimension; depth of invasion ≤5 mm
• T2 — tumor ≤2 cm with depth >5 mm, or tumor 2–4 cm with depth ≤10 mm
• T3 — tumor >4 cm, or any tumor with depth of invasion >10 mm
• T4a — moderately advanced local disease: lip/oral cavity tumor invades cortical bone, inferior alveolar nerve, floor of mouth, skin of face; or oropharynx tumor invades larynx, deep tongue muscles, medial pterygoid, hard palate, mandible
• T4b — very advanced local disease: masticator space, pterygoid plates, skull base, or internal carotid artery encasement

HPV-Positive Oropharyngeal Cancer (Separate System)

HPV-positive OPC uses a clinically-based (cTNM) and pathologically-based (pTNM) system with more favorable stage groupings. What would be Stage IV in other head and neck cancers may be Stage I–II in HPV-positive OPC, reflecting the dramatically better prognosis of this subtype.

Nodal Staging and Extranodal Extension

Extranodal extension (ENE) — tumor spreading beyond the lymph node capsule into surrounding soft tissues — was a major addition in AJCC 8th. ENE can be detected clinically (on CT/MRI as irregular nodal margins with surrounding fat stranding) or pathologically. Pathological ENE upgrades nodal disease to pN3b and is one of the strongest predictors of distant metastasis and death in oral cavity and HPV-negative OPC. It is a standard indication for adjuvant chemotherapy when present on surgical pathology.

Back to Table of Contents

Treatment — Surgery

Surgery is the primary treatment modality for oral cavity cancer and, increasingly, for selected oropharyngeal cancers — particularly with the advent of transoral robotic surgery (TORS).

Oral Cavity Cancer

Early T1–T2 oral cavity cancers are typically resected transorally (through the mouth) with adequate margins. The goal is achieving clear surgical margins — generally accepted as ≥5 mm for oral cavity SCC. Close or positive margins are strong indications for re-resection or adjuvant radiation.

For tongue cancers, the extent of resection depends on tumor depth and size:

• Partial glossectomy for small anterior tongue lesions
• Hemiglossectomy or total glossectomy for more extensive tumors
• Lip-split mandibulotomy provides access to posterior oral cavity tumors
• Mandibulectomy (marginal or segmental) when bone invasion is present

Transoral Robotic Surgery (TORS) for Oropharynx

TORS has revolutionized the surgical treatment of oropharyngeal cancer. The da Vinci robotic system's articulated arms and 3D high-definition visualization allow surgeons to resect tonsil and base of tongue tumors through the mouth with minimal morbidity — avoiding the disfiguring mandibulotomy or pharyngotomy previously required for oropharyngeal access. Key advantages include:

• Accurate pathological staging — crucial for guiding de-escalation decisions in HPV-positive OPC
• Faster recovery, shorter hospitalization, and less swallowing morbidity compared with open surgery
• Potential avoidance of chemotherapy in low-risk HPV-positive OPC when surgical margins are clear

Neck Dissection

Regional lymph node management is a central component of oral cancer surgery. For clinically node-negative (cN0) necks with >20% estimated risk of occult nodal metastasis (most T2+ oral cavity tumors), elective neck dissection is recommended to remove and pathologically evaluate regional nodes, allowing accurate staging and guiding adjuvant therapy decisions. For clinically node-positive (cN+) disease, therapeutic neck dissection is performed. Selective neck dissection of levels I–III is standard for oral cavity primaries; levels II–IV for oropharyngeal primaries.

Back to Table of Contents

Treatment — Radiation and Chemoradiation

Radiation therapy plays a central role in both the definitive (non-surgical) and adjuvant (post-surgical) treatment of oral and oropharyngeal cancers.

Adjuvant Radiation and Chemoradiation

After surgery, adjuvant radiation is indicated for locally advanced disease, close/positive margins, perineural invasion, lymphovascular invasion, and multiple positive nodes. The landmark 2004 New England Journal of Medicine trials by Bernier and Cooper (published simultaneously) established that concurrent cisplatin with adjuvant radiation significantly improves locoregional control and overall survival compared with radiation alone in patients with positive margins or extranodal extension — the two strongest indications for concurrent chemotherapy.

Definitive Chemoradiation for Oropharynx

Many oropharyngeal cancers — particularly HPV-positive tumors — are treated with definitive chemoradiation rather than primary surgery. The standard regimen is concurrent cisplatin (100 mg/m² every 3 weeks, or 40 mg/m² weekly) with 70 Gy intensity-modulated radiation therapy (IMRT) delivered over 7 weeks.

IMRT allows radiation oncologists to sculpt dose distributions precisely, sparing the parotid glands and reducing xerostomia (dry mouth) — a major improvement over older 3D conformal techniques. Parotid-sparing IMRT demonstrably reduces long-term xerostomia rates.

De-escalation in HPV-Positive OPC

Because HPV-positive OPC is so radiosensitive and cures are common, major trials have tested whether treatment intensity can be safely reduced to spare patients long-term toxicity:

• RTOG 1016 — tested cetuximab (an EGFR inhibitor) in place of cisplatin concurrently with radiation. Cetuximab was definitively inferior: worse survival and locoregional control. Cisplatin remains the standard concurrent agent; cetuximab should not be substituted for cisplatin in eligible patients.
• NRG HN002 — tested reduced-dose radiation (60 Gy) with or without weekly cisplatin in favorable-risk HPV-positive OPC. Results support a de-escalation approach in carefully selected patients.
• ECOG E3311 — TORS followed by risk-adapted adjuvant therapy (observation, reduced-dose radiation, or standard chemoradiation based on pathology). Established the feasibility of TORS-based de-escalation.
• ORATOR trial — comparable swallowing outcomes and survival for early T1–T2 OPC treated with surgery (TORS ± radiation) versus definitive radiation; no clear winner, supporting shared decision-making.

Key Radiation Toxicities

• Mucositis — painful inflammation of oral and pharyngeal mucosa; peaks at weeks 5–7; managed with analgesics, mucosa coating agents, and nutritional support.
• Xerostomia — dry mouth from parotid gland damage; can be permanent; IMRT and parotid-sparing techniques reduce severity.
• Dysphagia — swallowing dysfunction; the most functionally impactful late toxicity; requires swallowing rehabilitation and sometimes long-term feeding tube dependence.
• Osteoradionecrosis — necrosis of irradiated mandibular bone; risk increased by dental extractions after radiation, steroid use, and smoking; prevented by dental clearance and fluoride trays before radiation.
• Hypothyroidism — common after neck radiation; screen with TSH annually.

Back to Table of Contents

Systemic Therapy for Recurrent and Metastatic Disease

Approximately 30–40% of patients with locally advanced oral and oropharyngeal cancer will develop recurrent or metastatic disease. Median survival in the recurrent/metastatic setting has historically been poor, though immunotherapy has significantly improved outcomes for a subset of patients.

First-Line Therapy

The EXTREME regimen (platinum + 5-fluorouracil + cetuximab) was established by Vermorken and colleagues in 2008 (NEJM) as the standard first-line treatment for recurrent/metastatic head and neck SCC, improving median overall survival from 7.4 to 10.1 months compared with platinum/5-FU alone.

The 2019 KEYNOTE-048 trial (Burtness et al., Lancet) fundamentally changed first-line treatment:

• Pembrolizumab monotherapy — superior to EXTREME for patients with PD-L1 Combined Positive Score (CPS) ≥20; now preferred for this population, sparing chemotherapy toxicity.
• Pembrolizumab + platinum + 5-FU — superior to EXTREME for all patients regardless of PD-L1 status; now the preferred regimen for most patients requiring chemotherapy.
• The EXTREME regimen (with cetuximab) is no longer the preferred first-line option but remains an alternative for patients with contraindications to immunotherapy.

Second-Line and Beyond

• Nivolumab — FDA-approved for platinum-refractory recurrent/metastatic HNSCC (CheckMate 141 trial), with improved survival versus investigator's choice chemotherapy.
• Cetuximab monotherapy — for cisplatin-ineligible patients (e.g., renal insufficiency, hearing loss, neuropathy) as a less toxic alternative.
• Docetaxel or paclitaxel — standard taxane-based salvage chemotherapy.
• Methotrexate — used in very frail patients; modest activity, low toxicity.

HNSCC is generally immunogenic and expresses PD-L1, making it responsive to checkpoint inhibition. Tumor mutational burden (TMB) and PD-L1 CPS are used to guide immunotherapy selection, though neither is a perfect predictor.

Back to Table of Contents

Reconstruction and Quality of Life

Oral cavity cancer surgery can profoundly affect eating, speaking, swallowing, and appearance. Reconstruction is not cosmetic — it is functional, directly influencing a patient's ability to eat and communicate. The complexity of reconstruction scales with the size and location of the defect:

• Small defects — primary closure or split-thickness skin graft for defects where direct approximation is possible without restricting tongue movement.
• Moderate defects — local flaps such as the buccinator myomucosal flap or temporalis muscle flap for palate and posterior oral cavity defects.
• Large or complex defects — free flap microvascular reconstruction is the gold standard:
  • Radial forearm free flap — thin, pliable fasciocutaneous flap; ideal for tongue, floor of mouth, and buccal reconstruction where tongue mobility is paramount.
  • Anterolateral thigh (ALT) free flap — versatile, larger volume; suitable for extensive oropharyngeal and oral cavity defects.
  • Fibula free flap — provides vascularized bone; the preferred reconstruction for mandibular defects after segmental mandibulectomy, restoring jaw continuity and dental rehabilitation potential.

Functional Rehabilitation

• Speech-language pathology — swallowing therapy (both before and after treatment) reduces rates of long-term dysphagia; intensive pre-treatment swallowing exercises ("prehabilitation") are increasingly standard.
• Nutritional support — percutaneous endoscopic gastrostomy (PEG) tube placement during chemoradiation maintains nutritional status when oral intake is insufficient; prophylactic vs reactive tube placement is debated.
• Dental care — dental extraction of non-restorable teeth and fluoride tray fitting must be completed before radiation begins. Extracting teeth from an irradiated mandible risks osteoradionecrosis; fluoride trays reduce radiation-induced dental caries from xerostomia.
• Xerostomia management — saliva substitutes, pilocarpine (cholinergic stimulant), acupuncture (emerging evidence), and excellent oral hygiene.
• Psychosocial support — body image, relationship changes, depression, and anxiety are common; multidisciplinary care including social work and psychology improves quality of life.

Back to Table of Contents

Prevention and Early Detection

Oral cancer is among the most preventable cancers. The majority of HPV-negative cases are directly attributable to modifiable behaviors:

• Tobacco cessation — the single highest-impact intervention. Risk begins declining within years of quitting. All forms of tobacco — including smokeless — should be avoided.
• Alcohol reduction — reducing consumption below 14 drinks/week substantially lowers risk; complete abstinence in those already diagnosed with premalignant lesions is strongly advisable.
• HPV vaccination — Gardasil 9 (nonavalent HPV vaccine) protects against HPV-16 and HPV-18, the two types responsible for virtually all HPV-associated OPC. The FDA has approved vaccination through age 45 for catch-up immunization. Wider HPV vaccination coverage in adolescents is expected to reduce OPC incidence over the coming decades, mirroring reductions already seen in cervical cancer.
• Betel nut cessation — critical in at-risk South and Southeast Asian communities; oral submucous fibrosis may arrest or partially regress with cessation.
• Sun protection — lip balm with SPF and broad-brimmed hats for outdoor workers reduce lip cancer risk.

Screening and Early Detection

No large randomized controlled trial has demonstrated that population-level oral cancer screening reduces mortality. However, opportunistic screening by dentists and primary care physicians during routine visits — a brief visual and tactile oral examination — is widely recommended, costs nothing, and can detect premalignant lesions and early cancers that patients are unaware of.

Adjunctive technologies such as VELscope (fluorescence visualization) and Identafi (tissue fluorescence and reflectance) have been marketed to enhance mucosal lesion detection, but evidence of clinical benefit beyond conventional visual examination remains limited. They should not replace thorough clinical examination.

Monthly self-examination — patients using a mirror and flashlight to inspect the lips, tongue (including the undersurface and lateral borders), floor of mouth, cheeks, gums, and palate — can detect new lesions early. Any lesion persisting beyond 2 weeks should prompt professional evaluation.

Back to Table of Contents

Key Research Papers

1. Ang KK et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. PMID 20530316 — Landmark paper establishing HPV status as the dominant prognostic factor in OPC; defined HPV-positive OPC as a distinct disease entity with superior outcomes.
2. Vermorken JB et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer (EXTREME trial). N Engl J Med. 2008;359:1116–1127. PMID 18784101 — Established the EXTREME regimen as first-line standard for recurrent/metastatic HNSCC; improved median OS from 7.4 to 10.1 months.
3. Bernier J et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952. PMID 15128894 — EORTC 22931 trial; established concurrent cisplatin with adjuvant radiation as standard for positive margins and ENE.
4. Burtness B et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-048). Lancet. 2019;394:1915–1928. PMID 31679945 — Pembrolizumab ± chemotherapy superior to EXTREME; changed first-line standard of care in R/M HNSCC.
5. Mehanna H et al. Prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer — systematic review and meta-analysis of trends by time and region. Lancet Oncol. 2013;14:947–959. PMID 23946047 — Comprehensive meta-analysis documenting the global rise of HPV-positive OPC and regional variation.
6. Marur S et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–789. PMID 20451455 — Comprehensive review of the epidemiology and biology of HPV-driven head and neck cancer.
7. Fakhry C et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–269. PMID 18270337 — Prospective evidence of significantly better survival for HPV-positive HNSCC; reinforced the biological distinction.
8. Gillison ML et al. Cigarette smoking and alcohol use both independently increase risk of HPV-negative oropharyngeal cancer. J Clin Oncol. 2012;30:2360–2367. PMID 22585683 — Clarified the epidemiology of HPV-negative OPC as driven by tobacco and alcohol, distinct from HPV-positive OPC risk factors.
9. Mehanna H et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer (PET-NECK trial). N Engl J Med. 2016;374:1444–1454. PMID 27096590 — PET-CT at 12 weeks post-chemoradiation non-inferior to planned neck dissection; spares surgery in most patients with responding disease.
10. Cognetti DM et al. Transoral robotic surgery for oropharyngeal cancer. Otolaryngol Head Neck Surg. 2012;146:71–78. PMID 21930704 — Early outcomes data establishing TORS as a safe and effective approach for oropharyngeal resection.
11. Slaughter DP et al. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963–968. PMID 13094644 — Foundational paper introducing the field cancerization concept that underpins understanding of synchronous and metachronous second primaries.
12. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. PMID 25220842 — Global cancer burden data documenting the international oral cancer epidemic, including regional variation by betel nut use.

Back to Table of Contents

PubMed Topic Searches

• Oral squamous cell carcinoma treatment
• HPV oropharyngeal cancer prognosis
• Transoral robotic surgery TORS oropharynx
• Oral cancer de-escalation HPV positive
• Leukoplakia malignant transformation
• Oral cancer tobacco alcohol risk factors
• Pembrolizumab head and neck squamous cell carcinoma
• Free flap reconstruction oral cavity cancer
• Betel nut oral submucous fibrosis cancer
• IMRT head and neck xerostomia

Back to Table of Contents

Connections

• Cancer — Overview
• Skin Cancer
• Lung Cancer
• Esophageal Cancer
• Thyroid Cancer
• Stomach Cancer
• Cervical Cancer
• Liver Cancer
• Cholangiocarcinoma
• Breast Cancer

Back to Table of Contents

Featured Videos